Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. reports that its Phase 2b PARADIGM clinical trial of PrimeC has shown a promising 43% slowdown in disease progression for high-risk ALS patients, with consistent efficacy across different subgroups. The results, which also highlight a positive impact on newly diagnosed patients, may redefine ALS treatment standards if PrimeC gains approval after Phase 3 trials. These findings are expected to inform the design of the upcoming pivotal trial, aiming to enhance its success and cost-effectiveness.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
